Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
You need a consistent one
doi: 10.1210/en.2002-220405 126 MaidaAHansotiaTLonguetCSeinoYDruckerDJ
These materials are not intended for human consumption, medical use, or diagnostic purposes
Epigenetic Reprogramming: Making Neurodegeneration Reversible Sinclair's most consequential claim concerns OSK therapy Oct4, Sox2, and Klf4, three Yamanaka factors delivered in a partial reprogramming formulation called ER100
One strategy to improve the applicability of AD/ADRD trial data to more heterogeneous populations is to modify the exclusion criteria used when recruiting trial participants
US$ 28.72
US$ 21.96
:max_bytes(150000):strip_icc():focal(749x0:751x2)/gpl-1-jabs-052226-1-010a064224da4f85bf4c6ea0952739c8.jpg)
US$ 27.63
US$ 28.19
